• Open Access

DNA Self-Assembly of Targeted Near-Infrared-Responsive Gold Nanoparticles for Cancer Thermo-Chemotherapy

Authors

  • Dr. Zeyu Xiao,

    1. Laboratory of Nanomedicine and Biomaterials, Department of Anesthesiology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, 02115 (USA)
    2. MIT-Harvard Center for Cancer Nanotechnology Excellence, Massachusetts Institute of Technology, Cambridge, MA, 02139 (USA)
    Search for more papers by this author
  • Dr. Changwei Ji,

    1. Laboratory of Nanomedicine and Biomaterials, Department of Anesthesiology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, 02115 (USA)
    2. Department of Urology, The Affiliated Drum Tower Hospital of Nanjing, University Medical School, Nanjing, Jiangsu Province, 210008 (China)
    Search for more papers by this author
  • Dr. Jinjun Shi,

    1. Laboratory of Nanomedicine and Biomaterials, Department of Anesthesiology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, 02115 (USA)
    2. MIT-Harvard Center for Cancer Nanotechnology Excellence, Massachusetts Institute of Technology, Cambridge, MA, 02139 (USA)
    Search for more papers by this author
  • Eric M. Pridgen,

    1. The David H. Koch Institute for Integrative Cancer Research and Department of Chemical Engineering, Massachusetts Institute of Technology, Cambridge, MA, 02139 (USA)
    Search for more papers by this author
  • Jillian Frieder,

    1. Laboratory of Nanomedicine and Biomaterials, Department of Anesthesiology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, 02115 (USA)
    Search for more papers by this author
  • Dr. Jun Wu,

    1. Laboratory of Nanomedicine and Biomaterials, Department of Anesthesiology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, 02115 (USA)
    2. MIT-Harvard Center for Cancer Nanotechnology Excellence, Massachusetts Institute of Technology, Cambridge, MA, 02139 (USA)
    Search for more papers by this author
  • Prof. Omid C. Farokhzad

    Corresponding author
    1. Laboratory of Nanomedicine and Biomaterials, Department of Anesthesiology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, 02115 (USA)
    2. MIT-Harvard Center for Cancer Nanotechnology Excellence, Massachusetts Institute of Technology, Cambridge, MA, 02139 (USA)
    • Laboratory of Nanomedicine and Biomaterials, Department of Anesthesiology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, 02115 (USA)
    Search for more papers by this author

  • This research was supported by the National Institutes of Health under grant number CA151884 and the David Koch-Prostate Cancer Foundation Program in Cancer Nanotherapeutics. O.C.F. has financial interest in BIND Biosciences, Selecta Biosciences, and Blend Therapeutics, biopharmaceutical companies that are developing therapeutic nanoparticles.

Abstract

original image

Targeted cancer therapy: Inspired by the ability of DNA hybridization, a targeted near-infrared (NIR) light-responsive delivery system has been developed through simple DNA self-assembly (see picture; PEG=polyethylene glycol). This DNA-based platform shows the ability of releasing therapeutics upon near-infrared irradiation, and remarkable targeted thermo- and chemotherapeutic efficacy in vitro and in vivo.

Ancillary